Deferoxamine mesylate

別名: Ba 33112, Desferrioxamine B, DFOM, NSC 644468, DFO 中文名稱：甲磺酸去鐵胺

目錄號：S5742 Purity: 99.91%

Deferoxamine mesylate是Deferoxamine的甲磺酸鹽，它可形成鐵絡(luò)合物并用作螯合劑。Deferoxamine 是一種鐵死亡的抑制劑，可在體外低氧和高血糖狀態(tài)下穩(wěn)定 HIF-1α 的表達并改善HIF-1α的活性。Deferoxamine 可降低 beta-amyloid (Aβ) 的沉積并誘導(dǎo)自噬。請不要用生理鹽水或者PBS配制儲存液，可能會產(chǎn)生沉淀。

Deferoxamine mesylate Chemical Structure

CAS: 138-14-7

規(guī)格	價格	庫存
10mM (1mL in DMSO)	1122.65	現(xiàn)貨
25mg	1041.12	現(xiàn)貨
100mg	2596.23	現(xiàn)貨
1g	13570.83	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 info@selleck.cn

產(chǎn)品質(zhì)控

批次：純度： 99.91%

99.91

常與Deferoxamine mesylate一起在實驗中被使用的化合物

Z-VAD-FMK

Deferoxamine mesylate可以逆轉(zhuǎn)EMFF中顆粒細胞的細胞增殖活性，但不能逆轉(zhuǎn)Z-VAD-FMK。

Ni Z, et al. Cell Death Dis. 2022 Jul 4;13(7):579.

Fer-1 (Ferrostatin-1)

Deferoxamine mesylate和Ferrostatin-1可以逆轉(zhuǎn)EMFF中顆粒細胞的細胞增殖活性。

Ni Z, et al. Cell Death Dis. 2022 Jul 4;13(7):579.

SRS11-92

Deferoxamine mesylate可以逆轉(zhuǎn)EMFF中顆粒細胞的細胞增殖活性，但不能逆轉(zhuǎn)Necrostatin-1。

Ni Z, et al. Cell Death Dis. 2022 Jul 4;13(7):579.

Rosiglitazone

Deferoxamine mesylate和Rosiglitazone是鐵死亡的抑制劑并誘導(dǎo)自噬。

Deferoxamine mesylate相關(guān)產(chǎn)品

相關(guān)產(chǎn)品	Fer-1 (Ferrostatin-1) Erastin RSL3 Liproxstatin-1 FIN56 IKE(Imidazole ketone erastin) UAMC-3203 iFSP1 SRS16-86 SRS11-92	點擊展開
相關(guān)化合物庫	激酶抑制劑庫 FDA藥物庫天然產(chǎn)物庫已知活性藥物庫-I 高選擇性抑制劑庫	點擊展開

細胞實驗數(shù)據(jù)示例

細胞系	實驗類型	給藥濃度	孵育時間	活性描述	文獻信息
HT-29	Cell cycle assay	10 uM	24 hrs	Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 10 uM after 24 hrs	20353152
HT-29	Cell cycle assay	5 uM	24 hrs	Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 5 uM after 24 hrs	20353152
HeLa	Bacteriostatic assay	>100 uM	1 hr	Bacteriostatic activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as growth inhibition compound treated at >100 uM for 1 hr prior infection measured 24 hrs post infection by microscopy	25027937
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by LDH assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by LDH assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by MTT assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by MTT assay	28285915
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 4.51 μM.	17602603
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 5 μM.	19601577
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 7.35 μM.	19216562
A549	Antiproliferative assay		72 hrs	Antiproliferative activity at human A549 cells after 72 hrs by MTT assay, IC50 = 7.5 μM.	22861499
SK-N-MC	Antiproliferative assay		96 hrs	Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay, IC50 = 8.58 μM.	17064069
SK-N-MC	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 9.89 μM.	20303768
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 10 μM.	22861499
DMS53	Antiproliferative assay		72 hrs	Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay, IC50 = 10 μM.	22861499
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 12.5 μM.	22858101
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 16.81 μM.	28841514
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM.	21055950
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM.	22172311
U2OS	Function assay		30 mins	Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay, EC50 = 17.8 μM.	22172704
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay, IC50 = 21.63 μM.	23312948
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay, IC50 = 22.7 μM.	21846118
SK-N-MC	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 22.7 μM.	23276209
HT29	Cytotoxicity assay		72 hrs	Cytotoxicity against human HT29 cells after 72 hrs by MTS assay, IC50 = 36.1 μM.	18345610
HCT116	Function assay		24 hrs	Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3	24900837
MDCK	Toxicity assay			Toxicity in MDCK cells by MTT method, IC50 = 9.49 μM.	20041672
SK-MN-C	Antiproliferative assay			Antiproliferative activity against human SK-MN-C cells by MTT assay, IC50 = 12.05 μM.	18159922
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50 = 14.22 μM.	17963372
SK-N-MC	Toxicity assay			Toxicity in human SK-N-MC cells by MTT method, IC50 = 16.04 μM.	20041672
HL60	Cytotoxicity assay			Cytotoxicity against human HL60 cells by alamar blue assay, GI50 = 18.4 μM.	23266185
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells, IC50 = 22 μM.	19601577
K562	Cytotoxicity assay			Cytotoxicity against human K562 cells, GI50 = 33.1 μM.	23266185
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
點擊查看更多細胞系數(shù)據(jù)

生物活性

產(chǎn)品描述

靶點

HIF-1α ^[1]

Beta Amyloid ^[1]

Ferroptosis ^[2]

參考文獻
[1] Chuang Guo, et al. Front Aging Neurosci . 2015 Jun 2;7:104. [2] Xue Yao, et al. Neural Regen Res . 2019 Mar;14(3):532-541. [3] Li P, et al. Nat Immunol. 2021 Sep;22(9):1107-1117. [4] Sanan S, et al. Resuscitation. 1989 Feb;17(1):63-75. + 展開

參考文獻

[1] Chuang Guo, et al. Front Aging Neurosci . 2015 Jun 2;7:104.
[2] Xue Yao, et al. Neural Regen Res . 2019 Mar;14(3):532-541.
[3] Li P, et al. Nat Immunol. 2021 Sep;22(9):1107-1117.

[4] Sanan S, et al. Resuscitation. 1989 Feb;17(1):63-75.

+ 展開

化學(xué)信息&溶解度

分子量	656.79	分子式	C₂₆H₅₂N₆O₁₁S
CAS號	138-14-7	SDF	--
儲存條件(自收到貨起)	3年 -20°C 粉狀	儲備液保存和期限建議分裝儲備液，避免反復(fù)凍融！	1年-80°C溶于溶劑
儲存條件(自收到貨起)	3年 -20°C 粉狀	儲備液保存和期限建議分裝儲備液，避免反復(fù)凍融！	1個月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 100 mg/mL ( (152.25 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : 100 mg/mL (152.25 mM)

Ethanol : Insoluble

DMSO : 100 mg/mL ( (152.25 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : 100 mg/mL (152.25 mM)

Ethanol : Insoluble

DMSO : 100 mg/mL ( (152.25 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : 100 mg/mL (152.25 mM)

Ethanol : Insoluble

Water : 100 mg/mL (152.25 mM)

DMSO : 50 mg/mL ( (76.12 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Ethanol : Insoluble

摩爾濃度計算器

體內(nèi)溶解度
批次：

現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑

動物體內(nèi)配方計算器

實驗計算

摩爾濃度計算器

質(zhì)量	濃度	體積	分子量
=	×	×

稀釋計算器分子量計算器

動物體內(nèi)配方計算器（澄清溶液）

第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）

給藥劑量 mg/kg 動物平均體重 g 每只動物給藥體積 μL 動物數(shù)量只

第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。

操作手冊

如果有其他問題，請給我們留言。

* 必填項

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Deferoxamine mesylate

產(chǎn)品質(zhì)控

常與Deferoxamine mesylate一起在實驗中被使用的化合物

Deferoxamine mesylate相關(guān)產(chǎn)品

細胞實驗數(shù)據(jù)示例

生物活性

化學(xué)信息&溶解度

實驗計算

技術(shù)支持